In this issue:
Icotrokinra and deucravacitinib in moderate-to-severe plaque psoriasis
Clinical, genetic and protein markers to discriminate PsA from psoriasis
All-cause mortality with generalised pustular psoriasis
Guselkumab for moderate-to-severe psoriasis across all skin tones
Guselkumab for moderate-to-severe scalp psoriasis across all skin tones
TYK2/JAK inhibitor TLL-018 in moderate-to-severe plaque psoriasis
Subclinical synovitis among patients with psoriasis
Predictive factors for early super response to bimekizumab
Early apremilast initiation in psoriasis with limited skin involvement
IL-36γ measurement via tape stripping
Please login below to download this issue (PDF)